SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

SAN FRANCISCO, June 10, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of ENLIVEN, a

ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21 SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

- Received written guidance from FDA related to trial design and agreement to use liquid formulation - - ENLIVEN trial to initiate as planned in 2Q21 - SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 - - NASH histology cohort topline data expected by YE21 - - Phase 2 SHTG trial (ENTRIGUE) expected to report topline data in 2H21 - SAN FRANCISCO, March 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc.

New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH SAN FRANCISCO , March 20, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative

SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will